Celltrion, Inc.
068270
Kedudukan dalam Saham
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$146.63
Modal Pasaran
$33.44B
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
23.60%
Negara
KR
Perdagangan Celltrion, Inc. (068270)
Kategori
Healthcare
Sejarah dividen untuk Celltrion, Inc. (068270)
Celltrion, Inc. (simbol saham: 068270) telah membuat sejumlah 10 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $2.98K
Hasil dividen (TTM): 0.0037
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $2.98K
Hasil dividen (TTM): 0.0037
Pembayaran dividen untuk Celltrion, Inc. (068270) dari 2006 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (diselaraskan untuk pemecahan saham) | Ubah |
|---|---|---|
| 2026 (TTM) | $714.29 | 0.00% |
| 2025 | $714.29 | 9.20% |
| 2024 | $654.11 | 50.00% |
| 2023 | $436.07 | 33.33% |
| 2022 | $327.05 | -48.00% |
| 2021 | $628.95 | 3,764.42% |
| 2012 | $16.28 | -77.75% |
| 2011 | $73.14 | 33.33% |
| 2010 | $54.85 | 50.00% |
| 2007 | $36.57 | 0.00% |
| 2006 | $36.57 | 0.00% |
Senarai semua pembayaran dividen
| Tahun | Dividen | Ubah |
|---|---|---|
| 2026 (TTM) | $750.00 | 0.00% |
| 2025 | $750.00 | 4.00% |
| 2024 | $721.15 | 50.00% |
| 2023 | $480.77 | 28.21% |
| 2022 | $375.00 | -49.02% |
| 2021 | $735.58 | 5,056.73% |
| 2012 | $14.26 | -85.17% |
| 2011 | $96.15 | 33.33% |
| 2010 | $72.12 | 50.00% |
| 2007 | $48.08 | 0.00% |
| 2006 | $48.08 | 0.00% |
Pembayaran dividen untuk syarikat serupa atau pesaing
| Syarikat | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 67.00% |
AU
|
|
| 30.00% |
BE
|
|
| 0.00% |
NL
|
